📊 DSGN Key Takeaways
Is DSGN a Good Investment? Thesis Analysis
Design Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and no clear path to profitability. The company is burning through cash at an annual rate exceeding $54M with only $16.9M in cash reserves, presenting a critical runway issue that threatens operational continuity within the next fiscal period.
Why Buy DSGN? Key Strengths
- Strong balance sheet with minimal debt (0.00x Debt/Equity) and $212.5M stockholders' equity
- Excellent liquidity position with 17.14x current ratio providing near-term operational flexibility
- Substantial asset base of $226.2M indicating accumulated capital investments in R&D
DSGN Investment Risks to Consider
- Zero revenue generation with no commercial products, typical for early-stage biotech but creates existential cash burn risk
- Negative operating cash flow of -$54.4M annually with only $16.9M cash reserves implies critical funding runway of less than 4 months at current burn rate
- Negative ROE of -32.8% and ROA of -30.9% demonstrate value destruction with no near-term path to profitability based on available data
Key Metrics to Watch
- Cash runway and timing of next financing requirement
- Clinical trial progress and regulatory milestones for pipeline assets
- Quarterly operating cash burn trends and management of operating expenses
DSGN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 17.14x current ratio provides a solid financial cushion.
DSGN Profitability Ratios
DSGN vs Healthcare Sector
How Design Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DSGN Overvalued or Undervalued?
Based on fundamental analysis, Design Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DSGN Balance Sheet & Liquidity
DSGN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Design Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.88 indicates the company is currently unprofitable.
DSGN Growth Metrics (YoY)
DSGN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$13.0M | $-0.23 |
| Q2 2025 | N/A | -$11.8M | $-0.21 |
| Q1 2025 | N/A | -$11.1M | $-0.20 |
| Q3 2021 | $20.0K | -$2.3M | N/A |
| Q2 2021 | $31.0K | -$1.4M | N/A |
| Q1 2021 | $142.0K | -$663.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DSGN Capital Allocation
DSGN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Design Therapeutics, Inc. (CIK: 0001807120)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DSGN
What is the AI rating for DSGN?
Design Therapeutics, Inc. (DSGN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DSGN's key strengths?
Claude: Strong balance sheet with minimal debt (0.00x Debt/Equity) and $212.5M stockholders' equity. Excellent liquidity position with 17.14x current ratio providing near-term operational flexibility.
What are the risks of investing in DSGN?
Claude: Zero revenue generation with no commercial products, typical for early-stage biotech but creates existential cash burn risk. Negative operating cash flow of -$54.4M annually with only $16.9M cash reserves implies critical funding runway of less than 4 months at current burn rate.
What is DSGN's revenue and growth?
Design Therapeutics, Inc. reported revenue of $0.0.
Does DSGN pay dividends?
Design Therapeutics, Inc. does not currently pay dividends.
Where can I find DSGN SEC filings?
Official SEC filings for Design Therapeutics, Inc. (CIK: 0001807120) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DSGN's EPS?
Design Therapeutics, Inc. has a diluted EPS of $-1.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DSGN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Design Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DSGN stock overvalued or undervalued?
Valuation metrics for DSGN: ROE of -32.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DSGN stock in 2026?
Our dual AI analysis gives Design Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DSGN's free cash flow?
Design Therapeutics, Inc.'s operating cash flow is $-54.4M, with capital expenditures of $193.0K.
How does DSGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -32.8% (avg: 15%), current ratio 17.14 (avg: 2).